

Gynekologie

- 2** **Možnosti medikamentózní léčby hluboké endometriózy a endometriózy rektovaginálního septa**
MUDr. Kateřina Horváthová | prof. MUDr. Radovan Pilka, Ph.D.
UP v Olomouci, Porodnicko-gynekologická klinika LF a FN, Olomouc
- 2** **Současné možnosti a novinky v léčbě OAB**
prof. MUDr. Alois Martan, DrSc. Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha
- 2** **Novinky v hormonální antikoncepci**
MUDr. Michael Fanta, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha
- 3** **Zásady léčebné strategie u vulvovaginální kandidózy**
doc. MUDr. Jiří Špaček, Ph.D., IFEPAG Porodnická a gynekologická klinika FN a LF, Hradec Králové
- 3** **Je pokročilý a metastatický karcinom prsu chronicky léčitelné onemocnění?**
prof. MUDr. Jitka Abrahámová, DrSc. Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha
- 4** **Farmakoterapie klimakterického syndromu**
doc. MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha
- 4** **Poly-(ADP-ribózo)-polymeráza (PARP inhibitory) u karcinomu vaječníku**
MUDr. Mária Zvaríková Klinika komplexní onkologické péče MOÚ, Brno
- 5** **Novinky v léčbě a prevenci HPV infekce**
doc. MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha
- 5** **Karcinom děložního hrdla a HPV**
MUDr. Mgr. Igor Piňos, CSc.
- 5** **Rizika asistované reprodukce**
prof. ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha
- 6** **Antibiotika s úzkým, cíleným účinkem na bázi CRISPR-Cas**
prof. ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha
- 6** **Léčba bolesti u revmatologických onemocnění**
MUDr. Marek Hakl, Ph.D. Centrum pro léčbu bolesti ARK, LF MU a FN u sv. Anny v Brně,
Centrum léčby bolesti DH clinic, Brno-Komín
- 6** **Lymeská artritida**
MUDr. Helena Dejmková Revmatologický ústav, Mediscan, Praha

Možnosti medikamentózní léčby hluboké endometriózy a endometriózy rektovaginálního septa

MUDr. Kateřina Horváthová | prof. MUDr. Radovan Pilka, Ph.D.

UP v Olomouci, Porodnicko-gynekologická klinika LF a FN, Olomouc

- Kennedy, S. – Bergqvist, A. – Chapron, Ch., et al., on behalf of the ESHRE Special Interest Group for Endometriosis and Endometrium Guideline Development Group: ESHRE guideline for the diagnosis and treatment of endometriosis. *Human Reproduction*, 2005, 10, s. 2698–2704.
- Seher, A. K.: Drug therapy for endometriosis-associated pain. *US Pharm*, 2015, 40, s. H513–H517.
- The Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis. *Fertility and Sterility*, 2008, 90.
- Dostupné z: www.endometriosis.org/endometriosis/
- Koninckx, P. R. – Ussia, A. – Adamyan, L. – Wattiez, A. – Donnez, J.: *Fertil Steril*, 2012, 98, s. 564–571.
- Vercellini, P. – Crosignani, P. G. – Abbiati, A., et al.: The effect of surgery for symptomatic endometriosis: the other side of the story. *Hum Reprod Update*, 2009, 15, s. 177.
- Brosens, I. A.: Endometrióza – onemocnění charakterizované krvácením. *Prakt Gynek*, 1997, 3, s. 64–68.
- Vercellini, P. – Crosignani, P. G. – Somigliana, E., et al.: "Waiting for Godot": a commonsense approach to the medical treatment of endometriosis. *Human Reproduction*, 2011, 1, s. 3–13.
- Vercellini, P. – Frantino, G. – De Giorgi, O. – Aimi, G. – Zaina, B. – Crosignani, P. G.: Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. *Fertil Steril*, 2003, 80, s. 305–309.
- Seracchioli, R. – Mabrouk, M. – Frasca, C. – Manuzzi, L. – Savelli, L. – Venturoli, S.: Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. *Fertil Steril*, 2010, 94, s. 464–471.
- Dmowski, W. P. – Rolland, R.: *Endometriosis, emphasis on new treatment modalities*. Hoechst, 1989.
- Vercellini, P. – Crosignani, P. G. – Somigliana, E., et al.: Medical treatment for rectovaginal endometriosis: what is the evidence? *Hum Reprod*, 2009, 24, s. 2504.
- Vercellini, P. – Pietropaolo, G. – De Giorgi, O., et al.: Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. *Fertil Steril*, 2005, 84, s. 1375.
- Ferrero, S. – Camerini, G. – Ragni, N., et al.: Norethisterone acetate in the treatment of colorectal endometriosis: a pilot study. *Hum Reprod*, 2010, 25, s. 94.
- Fedele, L. – Bianchi, S. – Zanonato, G., et al.: Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. *Fertil Steril*, 2001, 75, s. 485.
- Vercellini, P. – Frantino, G. – De Giorgi, O., et al.: Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. *Fertil Steril*, 2003, 80, s. 560–563.
- Vercellini, P. – Barbara, G. – Somigliana, E. – Bianchi, S. – Abbiati, A. – Fedele, L.: Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. *Fertil Steril*, 2010, 93, s. 2150–2161.
- Ferrero, S., et al.: Dienogest in the treatment of rectovaginal endometriosis: effect on deep dyspareunia and sexual function. *Fertility and Sterility*, 2014, 102, dopl., s. e78.
- Vercellini, P. – Aimi, G. – Panazza, S. – De Giorgi, O. – Pesole, A. – Crosignani, P. G.: A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study. *Fertil Steril*, 1999, 72, s. 505–508.
- Vercellini, P. – Frantino, G. – De Giorgi, O. – Aimi, G. – Zaina, B. – Crosignani, P. G.: Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. *Fertil Steril*, 2003, 80, s. 305–309.
- Fedele, L. – Bianchi, S. – Zanonato, G. – Portuese, A. – Raffaelli, R.: Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. *Fertil Steril*, 2001, 75, s. 485–488.
- Fedele, L. – Bianchi, S. – Zanonato, G. – Tozzi, L. – Raffaelli, R.: Gonadotropin-releasing hormone agonist treatment for endometriosis of the rectovaginal septum. *Am J Obstet Gynecol*, 2000, 183, s. 1462–1467.
- Razii, S. – Luisi, S. – Calonaci, F. – Altomare, A. – Bocchi, C. – Petraglia, F.: Efficacy of vaginal danazol treatment in women with recurrent deeply infiltrating endometriosis. *Fertil Steril*, 2007, 88, s. 789–794, Epub červenec 2007.
- Hefler, L. A. – Grimm, C. – Van Trotsenburg, M. – Nagele, F.: Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study. *Fertil Steril*, 2005, 84, s. 1033–1036.
- Remorgida, V. – Abbamonte, H. L. – Ragni, N. – Fulcheri, N. – Ferrero, S.: Letrozole and norethisterone in rectovaginal endometriosis. *Fertil Steril*, 2007, 150, s. 199–202.

Současné možnosti a novinky v léčbě OAB

prof. MUDr. Alois Martan, DrSc. Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha

- Abrams, P. – Cardovo, L. – Fall, M., et al.: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. *Neurourological Urology*, 2002, 21, s. 167–178.
- Banner, J. S. – Nichol, M. B. – Rovner, E. S., et al.: Patient-reported reasons for discontinuing overactive bladder medication. *BJU International*, 2009, 105, s. 1276–1282.
- Buser, N. – Ivic, S. – Kessler, T. M., et al.: Efficacy and adverse events of antimuscarinics for treating overactive bladder: Network meta-analysis. *Eur Urol*, 2012, 62, s. 1040–1060.
- de Groat, W. C.: Integrative control of the lower urinary tract: preclinical perspective. *Br J Pharmacol*, 2006, 147, s. S25–S40.
- Chapple, Ch. R. – Kaplan, S. A. – Mitcheson, D., et al.: Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β_3 -adrenoceptor agonist, in overactive bladder. *Eur Urol*, 2013, 63, s. 296–305.
- Igawa, Y. – Aizawa, N. – Homma, Y., et al.: β_3 -adrenoceptor agonists: possible role in the treatment of overactive bladder. *Korean J Urol*, 2010, 51, s. 811–818.
- Khullar, V. – Amarengo, G. – Angulo, J. C., et al.: Efficacy and tolerability of mirabegron, a β_3 -adrenoceptor agonist, in patients with overactive bladder: Results from a randomised European-Australian phase 3 trial. *Eur Urol*, 2013, 63, s. 283–295.
- Martan, A. – Horčíčka, L. – Hanuš, T., et al.: Prevalence žen s hyperaktivním močovým měchýřem v České republice. *Čes Gynek*, 2011, 76, s. 144–150.
- Irwin, D. E. – Milsom, I. – Hunskaar, S., et al.: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries; results of EPIC study. *Eur Urol*, 2006, 50, s. 1306–1314.
- Shvarts, G. Y. – Shvarts, P. G. – Plotnikov, A. N. – Savvin, D. Y.: Drugs for the treatment of overactive bladder syndrome: present and future (a review). *Pharmaceutical Chemistry Journal*, 2013, 46, s. 699–706.
- Stewart, W. F. – Corey, R. – Herzog, A. R., et al.: Prevalence of overactive bladder in women: results from the NOBLE program. *Int Urogynaecol J*, 2001, 12, s. S66.
- Tikkinen, K. A. O. – Auvinen, A.: Does the imprecise definition of overactive bladder serve commercial rather than patient interests? *Eur Urol*, 2012, 61, s. 746–748.
- Tyagi, P. – Thomas, C. A. – Yoshimura, N., et al.: Investigations into the presence of functional Beta 1, Beta 2 and Beta 3-adrenoreceptors in urothelium and detrusor of human bladder. *Int Braz J Urol*, rok, 35, s. 76–83.
- Wesnes, K. A. – Edgar, C. – Tretter, R. N. – Bolodeoku, J.: Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin. *Expert Opin Drug Saf*, 2009, 8, s. 615–626.

Novinky v hormonální antikoncepci

MUDr. Michael Fanta, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha

- Meade, T. W. – Greenberg, G. – Thompson, S. G.: Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-microgram oestrogen preparations. *Br Med J*, 1980, 280, s. 1157–1161.
- Fanta, M.: Kombinovaná hormonální antikoncepce. *Postgraduální medicína*, 2009, 11, 4, s. 247–250.
- Fanta, M.: Novinky v hormonální antikoncepci. *Lékařské listy*, 2009, 9, s. 26–28.
- Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral, V.: Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. *Lancet*, 2008, 371, s. 303–314.
- Hannaford, P. C.: Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioners' oral contraception study. *BMJ*, 2007, 335, s. 651.
- Pearlstein, T. B. – Bachmann, G. A. – Zaccur, H. A., et al.: Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. *Contraception*, 2005, 72, s. 414–421.
- Yonkers, K. A. – Brown, C. – Pearlstein, T. B., et al.: Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. *Obstet Gynecol*, 2005, 106, s. 492–501.
- Parke, S.: Bleeding patterns and cycle control with a novel four-phasic COC containing estradiol valerate and dienogest + Efficacy and tolerability of an innovative four-phasic COC containing estradiol valerate and dienogest, 10th Congress of ESC, 2008.
- Bitzer, J., et al.: The CHOICE study: Effect of counselling on the selection of combined hormonal contraceptive methods in 11 countries. *Eu J Contraception Reprod Health Care*, 2012, 17, s. 65–78.
- Sulak, P. J. – Scow, R. D. – Preece, C., et al.: Hormone withdrawal symptoms in oral contraceptive users. *Obstet Gynecol*, 2000, 95, s. 261–266.
- Creinin, M. D.: Multicenter comparison of contraceptive ring and patch: randomized controlled trial. *Obstet Gynecol*, 2008, 111, s. 266–277.

12. *Medical Eligibility for Contraceptive Use*, A. vydání, 2010, www.who.int/reproductivehealth.
13. **Cepický, P. – Cibula, D., et al.**: Doporučení k předpisu kombinované hormonální antikoncepce, aktualizace 2005. *Čes Gynecol*, 2005, 70, s. 465–468.
14. **Westhoff, C., et al.**: Efficacy, safety, and tolerability of a monophasic oral contraceptive containing norgestrol acetate and 17 β -estradiol: a randomized controlled trial. *Obstet Gynecol*, 2012, 119, s. 989–999.
15. **Mansour, D. – Verhoeven, C. – Sommer, W., et al.**: Efficacy and tolerability of a monophasic combined oral contraceptive containing norgestrol acetate and 17 β -oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. *Eur J Contracept Reprod Health Care*, 2011, 16, s. 430–443.
16. **Gemzell-Danielson, K., et al.**: A Phase III single-arm study of a new 13.5 mg levonorgestrel intrauterine contraceptive system in postmenarcheal adolescents: An evaluation of efficacy, bleeding, user satisfaction and placement. *Fertil Steril ASRM Abstracts*, 102, 3, dopl., září 2014.

Zásady léčebné strategie u vulvovaginální kandidózy

doc. MUDr. Jiří Špaček, Ph.D., IFEPAG Porodnická a gynekologická klinika FN a LF, Hradec Králové

1. **Buchta, V. – Špaček, J. – Jílek, P.**: Antimykotická léčba. In: Špaček, J. – Buchta, V. – Jílek, P., et al.: *Vulvovaginální dyskomfort a poruchy poševního prostředí*. Praha, Grada, 2013, s. 289–317.
2. **Gross, E. W. – Park, S. – Perlin, D. S.**: Cross-Resistance of clinical isolates of *Candida albicans* and *Candida glabrata* to over-the-counter azoles used in the treatment of vaginitis. *Microb Drug Resist*, 2000, 6, s. 155–161.
3. **Doležal, M. – Buchta, V.**: Aktuální pohled na skupinu antimykotik. *Praktické lékařství*, 2006, 1, s. 10–14.
4. **Donders, G. – Bellen, G. – Byttebier, G., et al.**: Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDIF trial). *Am J Obstet Gynecol*, 2008, 199, 613, s. e1–e9.
5. **Donders, G. G. – Bellen, G. – Mendling, W.**: Management of recurrent vulvovaginal candidiasis as a chronic illness. *Gynecol Obstet Invest*, 2010, 70, s. 306–321.
6. **Friese, K. – Neumann, G. – Siebert, J.**: Topical antiseptics as an alternative in the treatment of acute vulvovaginal candidiasis. *Arch Gynecol Obstet*, 2003, 268, s. 194–197.
7. **Hammer, K. A. – Carson, C. F. – Riley, T. V.**: Antifungal effects of *Melaleuca alternifolia* (tea tree) oil and its components on *Candida albicans*, *Candida glabrata* and *Saccharomyces cerevisiae*. *J Antimicrob Chemother*, 2004, 53, s. 1081–1085.
8. **Haria, M. – Bryson, H. M.**: Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. *Drugs*, 1995, 49, s. 103–120.
9. **Hettiarachchi, N. – Ashbee, H. R. – Wilson, J. D.**: Prevalence and management of non-albicans vaginal candidiasis. *Sex Transm Infect*, 2010, 86, s. 99–100.
10. **Horowitz, B. J.**: Topical flucytosine therapy for chronic recurrent *Candida tropicalis* infections. *J Reprod Med*, 1986, 31, s. 821–824.
11. **Iavazzo, C. – Gkegkes, I. D. – Zarkada, I. M., et al.**: Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. *J Womens Health (Larchmt)*, 2011, 20, s. 1245–1255.
12. **Jovanovic, R. – Congema, E. – Nguyen, H. T.**: Antifungal agents vs. boric acid for treating chronic mycotic vulvovaginitis. *J Reprod Med*, 1991, 36, s. 593–597.
13. **Lauper, U.**: Genital candidosis. *Curr Probl Dermatol*, 1996, 24, s. 123–131.
14. **Mathesa, B. – Gross, E. – Dun, E., et al.**: Prevalence of vaginal colonization by drug-resistant *Candida* species in college-age women with previous exposure to over-the-counter azole antifungals. *Clin Inf Dis*, 2001, 33, s. E23–E27.
15. **Milne, J. D. – Warnock, D. W.**: Effect of simultaneous oral and vaginal treatment on the rate of cure and relapse in vaginal candidosis. *Br J Vener Dis*, 1979, 55, s. 362–365.
16. **Molteni, B. – D'Antuono, A. – Bandini, P., et al.**: Efficacy and tolerability of a new chlorhexidine-based vaginal gel in vaginal infections. *Curr Med Res Opin*, 2004, 20, s. 849–853.
17. **Nwokolo, N. C. – Boag, F. C.**: Chronic vaginal candidiasis. Management in the postmenopausal patient. *Drugs Aging*, 2000, 16, s. 335–339.
18. **Nystatin Multicenter Study Group**: Therapy of candidal vaginitis: the effect of eliminating intestinal *Candida*. *Am J Obstet Gynecol*, 1986, 155, s. 651–655.
19. **Pappas, P. G. – Kauffman, C. A. – Andes, D., et al.**: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis*, 2009, 48, s. 503–535.
20. **Philips, A. J.**: Treatment of non-albicans *Candida* vaginitis with amphotericin B vaginal suppositories. *Am J Obstet Gynecol*, 2005, 192, s. 2009–2012.
21. **Ray, D. – Goswami, R. – Banerjee, U., et al.**: Prevalence of *Candida glabrata* and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. *Diabetes Care*, 2007, 30, s. 312–327.
22. **Richter, S. S. – Galask, R. P. – Messer, S. A., et al.**: Antifungal susceptibilities of *Candida* species causing vulvovaginitis and epidemiology of recurrent cases. *J Clin Microbiol*, 2005, 42, s. 2155–2162.
23. **Singh, S. – Sobel, J. D. – Bhargava, P., et al.**: Vaginitis due to *Candida* krusei: epidemiology, clinical aspects, and therapy. *Clin Infect Dis*, 2002, 35, s. 1066–1070.
24. **Sivasubramanian, G. – Sobel, J. D.**: Refractory urinary tract and vulvovaginal infection caused by *Candida* krusei. *Int Urogynecol J Pelvic Floor Dysfunct*, 2009, 20, s. 1379–1381.
25. **Sobel, J. D.**: Management of recurrent vulvovaginal candidiasis: unresolved issues. *Curr Infect Dis Rep*, 2006, 8, s. 481–486.
26. **Sobel, J. D. – Faro, S. – Force, R. W., et al.**: Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. *Am J Obstet Gynecol*, 1998, 178, s. 203–211.
27. **Sobel, J. D. – Chaim, W. – Nagappan, V., et al.**: Treatment of vaginitis caused by *Candida glabrata*: use of topical boric acid and flucytosine. *Am J Obstet Gynecol*, 2003, 189, s. 1297–1300.
28. **Sobel, J. D. – Wiesenfeld, H. C. – Martens, M., et al.**: Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. *N Engl J Med*, 2004, 351, s. 876–883.
29. **Subissi, A. – Monti, D. – Togni, G., et al.**: Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. *Drugs*, 2010, 70, s. 2133–2152.
30. **Špaček, J. – Buchta, V.**: Itraconazole in the treatment of acute and recurrent vulvovaginal candidiasis: comparison of a 1-day and a 3-day regimen. *Mycoses*, 2005, 48, s. 165–171.
31. **Špaček, J. – Buchta, V. – Jílek, P., et al.**: Clinical aspects and luteal phase assessment in patients with recurrent vulvovaginal candidiasis. *Eur J Obstet Gyn Rep Biol*, 2007, 131, s. 198–202.
32. **Špaček, J. – Buchta, V. – Jílek, P., et al.**: *Vulvovaginální dyskomfort a poruchy poševního prostředí*. Praha, Grada, 2013.
33. **Watson, C. – Calabretto, H.**: Comprehensive review of conventional and non-conventional methods of management of recurrent vulvovaginal candidiasis. *Aust N Z J Obstet Gynaecol*, 2007, 47, s. 262–272.
34. **White, D. J. – Habib, A. R. – Vanthuyne, A., et al.**: Combined topical flucytosine and amphotericin B for refractory vaginal *Candida glabrata* infections. *Sex Transm Infect*, 2001, 77, s. 212–213.
35. **Dvořák, V. – Hlaváčková, O. – Malík, V., et al.**: Systémová enzymoterapie jako součást léčby recidivujících vulvovaginálních kandidóz: pět let sledování. *ACTA MEDICINAE*, 2013, 4, s. 12–13.

Je pokročilý a metastatický karcinom prsu chronicky léčitelné onemocnění?

prof. MUDr. Jitka Abrahámová, DrSc. Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

1. **Ismael, G. – Heft, R. – Muehlbauer, S., et al.**: Subcutaneous versus intravenous administration of (neo) adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. *Lancet Oncol*, 2012, 13, s. 869–878.
2. **Pivot, X. – Gligorov, J. – Miller, V., et al.**: Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PreHer): an open-label randomised study. *Lancet Oncol*, 2013, 14, s. 962–970.
3. **Baselga, J. – Cortes, L. – Kim, S. B., et al.**: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. *N Engl J Med*, 2012, 366, s. 109–119.
4. **Swain, S. M. – Kim, S. B. – Cortés, J., et al.**: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Oncol*, 2013, 14, s. 461–471.
5. **Swain, S. M. – Eser, M. S. – Cortés, J., et al.**: Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. *Oncologist*, 2013, 18, s. 257–264.
6. **Cortés, J. – Baselga, J. – Im, Y. H., et al.**: Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. *Ann Oncol*, 2013, 24, s. 2630–2635.
7. **Swain, S. M. – Baselga, J. – Kim, S. B., et al.**: Pertuzumab, trastuzumab, and docetaxel in HER-2 positive metastatic breast cancer. *N Engl J Med*, 2015, 372, s. 724–734.
8. **Verma, S. – Miles, D. – Gianni, L., et al.**: Trastuzumab emtansine for HER2-positive advanced breast cancer. *N Engl J Med*, 2012, 367, s. 1783–1791, erratum in *N Engl J Med*, 2013, 368, s. 2442.
9. **Welslau, M. – Diéras, V. – Sohn, J. H., et al.**: Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. *Cancer*, 2014, 120, s. 642–651.
10. **Krop, I. E. – Kim, S. B. – González-Martín, A., et al.**: Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. *Lancet Oncol*, 2014, 15, s. 689–699.
11. **Yardley, D. A. – Noguchi, S. – Pritchard, K. I., et al.**: Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer. BOLERO-2 final progression-free survival analysis. *Adv Ther*, 2013, 30, s. 870–884.
12. **Burris, H. A. – Lebrun, F. – Rugo, H. S., et al.**: Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. *Cancer*, 2013, 119, s. 1908–1915.
13. **Beck, J. T. – Gabriel, N. – Hortobagyi, M.**: Everolimus plus exemestane as first-line therapy in HR+, HER2- advanced breast cancer in BOLERO-2. *Breast Cancer Research and Treatment*, 2014, 143, s. 459–467.
14. **André, F. – O'Regan, R. – Ozguroglu, M., et al.**: Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. *The Lancet Oncology*, 2014, 15, s. 580–591.
15. **Cortes, J. – O'Shaughnessy, J. – Losech, D., et al.**: Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. *Lancet*, 2011, 377, s. 914–923.
16. **Kaufman, P. A. – Awada, A. – Twelves, Ch., et al.**: A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. *SABCS 2012*, pre-entance S6–6.

Farmakoterapie klimakterického syndromu

doc. MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha

- 1 Archem, D. F. – Baber, R. J. – Barlow, D., et al.: Updated IMS recommendations on postmenopausal hormone therapy and preventive strategie for midlife health. *Climacteric*, 2011, 14, s. 302–320.
- 2 Beral, V. – Banks, E. – Reeves, G.: Evidence from randomised trials on the long-term effects of hormone replacement therapy. *Lancet*, 360, 2002, s. 942–944.
- 3 Birkhauser, M. H. – Panay, N. – Archem, D. F., et al.: Updated recommendations for hormone replacement therapy in the peri- and postmenopause. *Climacteric*, 2008, 11, 2, s. 108–124.
- 4 Cardovo, L. – Bachmann, G. – McGlith, D., et al.: Metaanalysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. *Obstet Gynecol*, 1998, 92, s. 722–727.
- 5 Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and HRT. *Lancet*, 1997, 350, s. 1047–1059.
- 6 Collins, P. – Rosano, G. – Casey, C., et al.: Management of cardiovascular risk in peri-menopausal woman. *Eur Heart J*, 2007, 28, s. 2028–2040.
- 7 Fait, T. – Donát, J. – Jeniček, J., et al.: Doporučení pro hormonální substituční terapii v postmenopauze. *Čes Gynek*, 2010, 75, 2, s. 109–110.
- 8 Furber, C. D. – Vittinghoff, E. – Davidson, M., et al.: Subgroup interactions in the heart and estrogen/progestin replacement study. *Circulation*, 2002, 105, s. 917–922.
- 9 Grady, D. – Herrington, D. – Bittner, V.: Heart and estrogen/progestin replacement study follow-up (HERS II). Cardiovascular disease outcomes during 6–8 years of hormone therapy. *JAMA*, 2002, 288, s. 49–57.
- 10 Hodis, H. N. – Collins, P. – Mack, W. J. – Schierbeck, L. L.: The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future perspective. *Climacteric*, 2012, 15, s. 217–228.
- 11 Hoibraaten, E.: Increased risk in recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo controlled estrogen in venous thromboembolism trial (EVET). *Tromb Haemost*, 2000, 84, s. 961–967.
- 12 Halley, S. – Grady, D. – Bush, T., et al.: Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. *JAMA*, 1998, 280, s. 605–613.
- 13 Mendelsohn, M. E. – Karas, R. H.: The Time Has Come to stop letting the HERS tale wag the dogma. *Circulation*, 2001, 104, s. 2256–2259.
- 14 Rossouw, J. E. – Prentice, R. L. – Manson, J. E., et al.: Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. *JAMA*, 2002, 297, s. 1465–1477.
- 15 Salpeter, S. R. – Walsh, J. M. – Greyber, E., et al.: Mortality associated with HRT in younger and older women. *J Gen Intern Med*, 2004, 19, s. 791–804.
- 16 Speroff, L. – Fritéz, M. A.: *Clinical gynecologic endocrinology and infertility*. Williams and Wilkins, Philadelphia, 2005.
- 17 The Women's Health Initiative Steering Committee: Effects of CEE in postmenopausal women with hysterectomy. *JAMA*, 2004, 291, s. 1701–1712.
- 18 The Writing Group for the PEPi Trial: Effect of estrogen or estrogen/progestin regimens on heart disease factors in postmenopausal women. *JAMA*, 1995, 273, s. 199–208.
- 19 WHI Steering Committee: Effect of CEE in postmenopausal women with hysterectomy. *JAMA*, 2004, 291, s. 1701–1712.
- 20 Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA*, 2002, 288, 3, s. 321–333.

Poly-(ADP-ribozo)-polymeráza (PARP inhibitory) u karcinomu vaječníku

MUDr. Mária Zvaríková Klinika komplexní onkologické péče MOÚ, Brno

- 1 Miki, Y. – Swensen, J. – Shattuck-Eidens, D. – Futreal, P. A., et al.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science*, 1994, 266, s. 66–71.
- 2 Wooster, R. – Bignell, G. – Lancaster, J. – Shift, S., et al.: Identification of the breast cancer susceptibility gene BRCA2. *Nature*, 1995, 378, s. 789–792.
- 3 Alsop, K. – Fereday, S. – Meldrum, C. – deFazio, A., et al.: BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. *J Clin Oncol*, 2012, 30, s. 2654–2663.
- 4 Concorsium CBCC-C: CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. *Am J Hum Genet*, 2004, 74, s. 1175–1182.
- 5 Seal, S. – Thompson, D. – Renwick, A., et al.: Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. *Nat Genet*, 2006, 38, s. 1239–1241.
- 6 Renwick, A. – Thompson, D. – Seal, S. – Kelly, P. – Chagtai, T., et al.: ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. *Nat Genet*, 2006, 38, s. 873–875.
- 7 Steffen, J. – Nowakowska, D. – Niwinska, A., et al.: Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland. *Int J Cancer*, 2006, 119, s. 472–475.
- 8 Rahman, N. – Seal, S. – Thompson, D. – Kelly, P., et al.: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. *Nat Genet*, 2007, 39, s. 165–167.
- 9 Mendl, A. – Hellebrand, H. – Piek, C., et al.: Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. *Nat Genet*, 2010, 42, s. 410–414.
- 10 De Brakeleer, S. – De Grepe, J. – Loris, R., et al.: Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families. *Hum Mutat*, 2010, 31, s. E1175–E1185.
- 11 Damokla, F. – Pertusi, M. – Olivek, J., et al.: Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study. *Breast Cancer Res*, 2014, 16, s. R58.
- 12 Rafnar, T. – Gudbjartsson, D. F. – Sulem, P., et al.: Mutations in BRIP1 confer high risk of ovarian cancer. *Nat Genet*, 2011, 43, s. 1104–1107.
- 13 Loveday, C. – Turnbull, C. – Ramsay, E., et al.: Germline mutations in RAD51D confer susceptibility to ovarian cancer. *Nat Genet*, 2011, 43, s. 879–882.
- 14 Walsh, T. – Casadei, S. – Lee, M. K., et al.: Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. *Proc Natl Acad Sci U S A*, 2011, 108, s. 18032–18037.
- 15 Valerie, K. – Povirk, L. F.: Regulation and mechanisms of mammalian double-strand break repair. *Oncogene*, 2003, 22, s. 5792–5812.
- 16 Sung, P. – Klein, H.: Mechanism of homologous recombination: mediators and helicases take on regulatory functions. *Nat Rev Mol Cell Biol*, 2006, 7, s. 739–750.
- 17 Krejci, L. – Altmanova, V. – Spirek, M. – Zhao, X.: Homologous recombination and its regulation. *Nucleic Acids Res*, 2012, 40, s. 5795–5818.
- 18 Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. *Nature*, 2011, 474, s. 609–615.
- 19 Turner, N. – Tutt, A. – Ashworth, A.: Hallmarks of 'BRCAness' in sporadic cancers. *Nat Rev Cancer*, 2004, 4, s. 814–819.
- 20 Cass, I. – Baldwin, R. L. – Varkey, T., et al.: Improved survival in women with BRCA-associated ovarian carcinoma. *Cancer*, 2003, 97, s. 2187–2195.
- 21 Chetiv, A. – Hirsh-Yechezkel, G. – Ben-David, Y. – Lubin, F. – Friedman, E., et al.: Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. *J Clin Oncol*, 2008, 26, s. 20–25.
- 22 Yang, D. – Khan, S. – Sun, Y. – Hess, K., et al.: Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. *JAMA*, 2011, 306, s. 1557–1565.
- 23 Bolton, K. L. – Chenevix-Trench, G. – Goh, C., et al.: Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. *JAMA*, 2012, 307, s. 382–390.
- 24 Pennington, K. P. – Walsh, T. – Harrell, M. I., et al.: Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. *Clin Cancer Res*, 2014, 20, s. 764–775.
- 25 Safra, T. – Borgato, L. – Nicoletto, M. O., et al.: BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. *Mol Cancer Ther*, 2011, 10, s. 2000–2007.
- 26 d'Adda di Fagana, F. – Hande, M. P. – Tong, W. M., et al.: Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability. *Nat Genet*, 1999, 23, s. 76–80.
- 27 Tong, W. M. – Cortes, U. – Wang, Z. Q.: Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis. *Biochim Biophys Acta*, 2001, 1552, s. 27–37.
- 28 Helleday, T. – Petermann, E. – Lundin, C., et al.: DNA repair pathways as targets for cancer therapy. *Nat Rev Cancer*, 2008, 8, s. 193–204.
- 29 Weil, M. K. – Chen, A. P.: PARP inhibitor treatment in ovarian and breast cancer. *Curr Probl Cancer*, 2011, 35, s. 7–50.
- 30 Sudeb, M. W. – Carmichael, J. – Penson, R. T., et al.: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. *Lancet*, 2010, 376, s. 245–251.
- 31 Fong, P. C. – Boss, D. S. – Yap, T. A., et al.: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med*, 2009, 361, s. 123–134.
- 32 Fong, P. C. – Yap, T. A. – Boss, D. S., et al.: Poly(ADP-ribose) polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. *J Clin Oncol*, 2010, 28, s. 2512–2519.
- 33 Audeh, M. W. – Carmichael, J. – Penson, R. T., et al.: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. *Lancet*, 2010, 376, s. 245–251.
- 34 Tutt, A. – Robson, M. – Garber, J. E., et al.: Oral poly(ADP-ribose) polymerase inhibitor Olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. *Lancet*, 2010, 376, s. 235–244.
- 35 Gelmon, K. A. – Tischkowitz, M. – Mackay, H., et al.: Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. *Lancet Oncol*, 2011, 12, s. 852–861.
- 36 Kaye, S. – Lubinski, J. – Matulonis, U., et al.: Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly(ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. *J Clin Oncol*, 2012, 30, s. 372–379.
- 37 Ledermann, J. – Harter, P. – Gourley, C., et al.: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. *Lancet Oncol*, 2014, 15, s. 852–861.
- 38 Liu, J. F. – Konstantinoulou, P. A. – Matulonis, U. A.: PARP inhibitors in ovarian cancer: current status and future promise. *Gynecol Oncol*, 2014, 133, s. 362–369, doi: 10.1016/j.ygyno.2014.02.039, Epub 4. 3. 2014, PMID: 24607283.
- 39 Oza, A. M. – Cibula, D. – Benzaquen, A. O., et al.: Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. *Lancet Oncol*, 2015, 16, s. 87–97, doi: 10.1016/S1470-2045(14)71135-0, Epub 4. 12. 2014, Erratum in: *Lancet Oncol*, 2015, 16, s. e55; *Lancet Oncol*, 2015, 16, s. e6.
- 40 Dean, E. – Middleton, M. R. – Pwint, T., et al.: Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumors. *Br J Cancer*, 2012, 106, s. 468–474.
- 41 Matulonis, U. A. – Berlin, S. – Ivy, P., et al.: Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube and peritoneal cancer. *Original Research, Onco-Nephrology*, 2009, 27, s. 5601–5606.
- 42 Liu, J. F. – Tolane, S. M. – Birrer, M., et al.: A phase I trial of the

poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triplenegative breast cancer. *Eur J Cancer*, 2013, 49, s. 2972–2978.

43 Liu, J. F. – Barry, W. T. – Birrer, M., et al.: Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. *Lancet Oncology*, 2014, 11, s. 1207–1214.

44 Kolasa, I. K. – Rembiszewska, A. – Felisiak, A., et al.: PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. *Cancer Biol Ther*, 2009, 8, s. 21–26.

Novinky v léčbě a prevenci HPV infekce

doc. MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha

- 1 Česká akademie dermatovenerologie: Léčba kondylomata acuminata v ČR. *Česká dermatovenerologie*, 2012, 2, s. 4.
- 2 Dobson, S. R., et al.: Immunogenicity of 2 doses of HPV vaccine in younger adolescent vs 3 doses in young women. *JAMA*, 2013, 309, s.

- 1793–1802.
- 3 Koutsky, L.: Epidemiology of genital human papillomavirus infection. *Am J Med*, 1997, 102, s. 3–8.
- 4 Lacey, C. J. N. – Woodhall, S. C. – Wikstrom, A. – Ross, J.: 2012

European guideline for the management of anogenital warts. *JEADV*, 2013, 27, s. 263–267.

- 5 Litvik, R.: Anogenitální akuminátní kondylomata. In: Fait, T.: *Očkování proti lidským papilomavírům*. Maxdorf, Praha, 2009, s. 21–36.

Karcinom děložního hrdla a HPV

MUDr. Mgr. Igor Piňos, CSc.

- 1 Rebolj, M., et al.: Disagreement between Human Papillomavirus Assays: An Unexpected Challenge for the Choice of an Assay in Primary Cervical Screening. *PLoS ONE*, 2014, 9, s. e86835, doi:10.1371/journal.pone.0086835.
- 2 Cuzick, J., et al.: Comparing the performance of six human

- papillomavirus tests in a screening population. *British Journal of Cancer*, 2013, 108, s. 908–913, doi: 10.1038/bjc.2013.22.
- 3 Ronco, G., et al.: Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. *Lancet*, 2014, 383, s. 524–532, dx.doi.org/10.1016/

S0140-6736(13)62218–7.

- 4 Katki, H. A. – Kinney, W. K. – Fetterman, B., et al.: Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. *Lancet Oncol*, 2011, 12, s. 663–672.

Rizika asistované reprodukce

prof. ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

- 1 Servick, S.: Unsettled questions trail IVF's success. *Science*, 2014, 345, s. 744–746.
- 2 Rinaudo, P. – Schultz, R. M.: Effects of embryo culture on global pattern of gene expression in preimplantation mouse embryos. *Reproduction*, 2004, 128, s. 301–311.
- 3 Rinaudo, P. F. – Giritharan, G. – Talbi, S. – Dobson, A. T. – Schultz, R. M.: Effects of oxygen tension on gene expression in preimplantation mouse embryos. *Fertility and Sterility*, 2006, 86, s. 1252–1265.
- 4 Giritharan, G. – Li, M. W. – Di Sebastiano, F. – Esteban, F. J. – Horcajadas, J. A. – Lloyd, K. C. – Donjacour, A. – Maltepe, E. – Rinaudo, P. F.: Effect of ICSI on gene expression and development of mouse preimplantation embryos. *Human Reproduction*, 2010, 25, s. 3012–3024.
- 5 Pandey, S. – Shetty, A. – Hamilton, M. – Bhattacharya, S. – Maheshwari, A.: Obstetric and perinatal outcomes in singleton pregnancies resulting from IVF/ICSI: a systematic review and meta-analysis. *Human Reproduction Update*, 2012, 18, s. 485–503.
- 6 Fernández-Gonzalez, R. – Moreira, P. – Bilbao, A. – Jiménez, A. – Pérez-Crespo, M. – Ramírez, M. – De Fonseca, F. – Pintado, B. – Gutiérrez-Adán, A.: Long-term effect of in vitro culture of mouse embryos with serum on mRNA expression of imprinting genes, development, and behavior. *Proceedings of the National Academy of Sciences USA*, 2004, 101, s. 5880–5885.
- 7 Barker, D. J. P. – Osmond, C. – Winter, P. D. – Margetts, B. – Simmonds, S. J.: Weight in infancy and death from ischaemic heart disease. *Lancet*, 1989, 303, s. 577–580.
- 8 Hales, C. N. – Barker, D. J. – Clark, P. M. – Cox, L. J. – Fall, C. – Osmond, C. – Winter, P. D.: Fetal and infant growth and impaired glucose tolerance. *British Medical Journal*, 1991, 303, s. 1474–1475.

- 9 Law, C. M. – Shiell, A. W.: Is blood pressure inversely related to birth weight? The strength of evidence from a systematic review of the literature. *Journal of Hypertension*, 1996, 14, s. 935–941.
- 10 Barker, D. J. P.: Fetal origins of coronary heart disease. *British Medical Journal*, 1995, 311, s. 171–174.
- 11 Kwong, W. Y. – Wild, A. E. – Roberts, P. – Willis, A. C. – Fleming, T. P.: Maternal undernutrition during the preimplantation period of rat development causes blastocyst abnormalities and programming of postnatal hypertension. *Development*, 2000, 27, s. 4195–4202.
- 12 Harris, S. E. – Gopichandran, N. – Picton, H. M. – Leese, H. J. – Orsi, N. M.: Nutrient concentrations in murine follicular fluid and the female reproductive tract. *Theriogenology*, 2005, 64, s. 992–1006.
- 13 El Hajj, N. – Haaf, T.: Epigenetic disturbances in in vitro cultured gametes and embryos: implications for human assisted reproduction. *Fertility and Sterility*, 2013, 99, s. 632–641.
- 14 Grace, K. S. – Sinclair, K. D.: Assisted reproductive technology, epigenetics, and long-term health: a developmental time bomb still ticking. *Seminars in Reproductive Medicine*, 2009, 27, s. 409–416.
- 15 Huntriss, J. – Picton, H. M.: Epigenetic consequences of assisted reproduction and infertility on the human preimplantation embryo. *Human Fertility*, 2008, 11, s. 85–94.
- 16 Rinaudo, P. – Wang, E.: Fetal programming and metabolic syndrome. *Annual Review of Physiology*, 2012, 74, s. 107–130.
- 17 Feuer, S. K. – Camarano, L. – Rinaudo, P. F.: ART and health: clinical outcomes and insights on molecular mechanisms from rodent studies. *Molecular Human Reproduction*, 2013, 19, s. 189–204.
- 18 Gicquel, C. – Gaston, V. – Mandelbaum, J. – Siffroi, J. P. – Flahault, A. – Le Bouc, Y.: In vitro fertilization may increase the risk of

- Beckwith-Wiedemann syndrome related to the abnormal imprinting of the KCN10T gene. *American Journal of Human Genetics*, 2003, 72, s. 1338–1341.
- 19 Amor, D. J. – Halliday, J.: A review of known imprinting syndromes and their association with assisted reproduction technologies. *Human Reproduction*, 2008, 23, s. 2826–2834.
- 20 Cox, G. F. – Bürger, J. – Lip, V. – Mau, U. A. – Sperling, K. – Wu, B. L. – Horsthemke, B.: Intracytoplasmic sperm injection may increase the risk of imprinting defects. *American Journal of Human Genetics*, 2002, 71, s. 162–164.
- 21 Feuer, S. K. – Camarano, L. – Rinaudo, P. F.: ART and health: clinical outcomes and insights on molecular mechanisms from rodent studies. *Molecular Human Reproduction*, 2013, 19, s. 189–204.
- 22 Kapiteijn, K. – de Bruijn, C. S. – de Boer, E. – de Craen, A. J. – Burger, C. W. – van Leeuwen, F. E. – Helmerhorst, F. M.: Does subfertility explain the risk of poor perinatal outcome after IVF and ovarian hyperstimulation? *Human Reproduction*, 2006, 21, s. 3228–3234.
- 23 Ceelen, M. – van Weissenbruch, M. M. – Prein, J. – Smit, J. J. – Vermeiden, J. P. – Spreuwenberg, M. – van Leeuwen, F. E. – Delemarre-van de Waal, H. A.: Growth during infancy and early childhood in relation to blood pressure and body fat measures at age 8–18 years of IVF children and spontaneously conceived controls born to subfertile parents. *Human Reproduction*, 2009, 24, s. 2788–2895.
- 24 Davies, M. J. – Moore, V. M. – Willson, K. J. – Van Essen, P. – Priest, K. – Scott, H. – Haan, E. A. – Chan, A.: Reproductive technologies and the risk of birth defects. *New England Journal of Medicine*, 2012, 366, s. 1803–1813.

Antibiotika s úzkým, cíleným účinkem na bázi CRISPR-Cas

prof. ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

- 1 Spellberg, B. – Bartlett, J. G. – Gilbert, D. N.: The future of antibiotics and resistance. *New England Journal of Medicine*, 2013, 368, s. 299–302.
- 2 Silver, L. L.: Antibacterials for any target. *Nature Biotechnology*, 2014, 32, s. 1102–1104.
- 3 Tipparaju, S. K. – Joyasawal, S. – Forrester, S. – Mulhearn, D. C. – Pegan, S. – Johnson, M. E. – Meseccar, A. D. – Kozikowski, A. P.: Design and synthesis of 2-pyridones as novel inhibitors of the *Bacillus anthracis* enoyl-ACP reductase. *Bioorganic and Medicinal Chemistry Letters*, 2008, 18, s. 3565–3569.
- 4 Yum, J. H. – Kim, C. K. – Yong, D. – Lee, K. – Chong, Y. – Kim, C. M. – Kim, J. M. – Ro, C. – Cho, J. M.: In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea. *Antimicrobial Agents and Chemotherapy*, 2007, 51, s. 2591–2593.
- 5 Werneburg, M. – Zerbe, K. – Juhas, M. – Bigler, L. – Stalder, U. – Kaech, A. – Ziegler, U. – Obrecht, D. – Eberl, L. – Robinson, J. A.: Inhibition of lipopolysaccharide transport to the outer membrane in *Pseudomonas aeruginosa* by peptidomimetic antibiotics. <http://www.ncbi.nlm.nih.gov/pubmed/22807320>, *ChemBioChem*, 2012, 13, s. 1767–1775.
- 6 Cho, I. – Laser, M. J.: The human microbiome: at the interface of health and disease. *Nature Reviews Genetics*, 2012, 13, s. 260–270.
- 7 Sander, J. D. – Joung, J. K.: CRISPR-Cas systems for editing, regulating and targeting genomes. *Nature Biotechnology*, 2014, 32, s. 347–355.
- 8 Jinek, M. – Chylinski, K. – Fonfara, I. – Hauer, M. – Doudna, J. A. – Charpentier, E.: A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science*, 2012, 337, s. 816–821.
- 9 Goma, A. A. – Klumpe, H. E. – Luo, M. – Selle, K. – Barrangou, R. – Beisel, C. L.: Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems. *mBio*, 2014, 5, s. e00928–e01013.
- 10 Citorik, R. J. – Mimee, M. – Lu, T. K.: Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. *Nature Biotechnology*, 2014, 32, s. 1141–1145.
- 11 Bikard, D. – Euler, C. W. – Jiang, W. – Nussenzweig, P. M. – Goldberg, G. W. – Duportet, X. – Fischetti, V. A. – Marraffini, L. A.: Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. *Nature Biotechnology*, 2014, 32, s. 1146–1150.

Léčba bolesti u revmatologických onemocnění

MUDr. Marek Hakl, Ph.D. Centrum pro léčbu bolesti ARK, LF MU a FN u sv. Anny v Brně,
Centrum léčby bolesti DH clinic, Brno-Komín

- 1 World Health Organisation. *Cancer Pain Relief: with a guide to opioid availability*, 1986.
- 2 Doležal T. – Hakl, M. – Kozák, J. – Kršiák, M. – Lejčko, J. – Skála, B. – Sláma, O. – Ševčík, P. – Vorlíček, J.: Metodické pokyny pro farmakoterapii bolesti. *Bolest*, 2009, 2, dopl., s. 4–27.
- 3 Chan, F. – Lanas, A. – Scheiman, J., et al.: Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis: a randomised trial. *Lancet*, publikováno online 17. 6. 2010, doi: 10.1016/S0140-6736(10)60673-3.

Lymeská artritida

MUDr. Helena Dejmková Revmatologický ústav, Mediscan, Praha

- 1 Rahn, D. W.: Lyme disease: Clinical manifestations, diagnosis, and treatment. *Sem Arthritis Rheum*, 1991, 20, s. 201–218.
- 2 Baranton, G. – Postic, D., et al.: Delineation of *Borrelia burgdorferi* sensu stricto, *Borrelia garinii* sp. nov., and group VS461 associated with Lyme borreliosis. *Int J Syst Bacteriol*, 1992, 42, s. 378–383.
- 3 Steere, A. C.: Lyme disease. *N Engl J Med*, 2001, 345, s. 115–125.
- 4 Van Dam, A. P. – Kuiper, H. – Vos, K., et al.: Different genospecies of *Borrelia burgdorferi* are associated with distinct clinical manifestations of Lyme borreliosis. *Clin Infect Dis*, 1993, 17, s. 708–717.
- 5 Londoño, D. – Cadavid, D., et al.: Antibodies to endothelial cell growth factor and obliterative microvascular lesions in synovia of patients with antibiotic-refractory Lyme arthritis. *Arthritis Rheumatol*, 2014, doi: 10.1002/art.38618 (Epub před tiskem).
- 6 Bojar, M.: *Lymeská borelióza*. Maxdorf, Praha, 1996.
- 7 Bartůněk, P.: *Lymeská karditida*. Grada, Praha, 1996.
- 8 Hercogová, J.: Postižení kůže. In: Bartůněk, P.: *Lymeská borelióza*. Praha, Grada, 1996.
- 9 Valešová, M.: *Lymeská artritida*. Grada, Praha, 1999.
- 10 Steere, A. C. – Dwyer, E. – Winchester, R.: Association of chronic Lyme arthritis with HLA-DR4 and HLA-DR2 alleles. *N Engl J Med*, 1990, 323, s. 219–223.
- 11 Kalish, R. A. – Leong, J. M. – Steere, A. C.: Association of treatment resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of *Borrelia burgdorferi*. *Infect Immun*, 1993, 61, s. 2774–2779.
- 12 Limbach, F. X. – Jaulhac, B., et al.: Treatment resistant Lyme arthritis caused by *Borrelia garinii*. *Ann Rheum Dis*, 2001, 60, s. 284–286.
- 13 Guerau-de-Arellano, M. – Huber, B. T.: Development of autoimmunity in Lyme arthritis. *Curr Opin Rheumatol*, 2002, 14, s. 388–393.
- 14 Asch, E. S. – Bujak, D. I. – Weiss, M., et al.: Lyme disease: an infectious and post infectious syndrome. *J Rheumatol*, 1994, 21, s. 454–461.
- 15 Marques, A.: Chronic Lyme disease: An appraisal. *Infect Dis Clin North Am*, 2008, 22, s. 341–360.
- 16 Rahn, D. W. – Malawista, S. E.: Lyme disease: Recommendations for diagnosis and treatment. *Ann Intern Med*, 1991, 114, s. 472–481.
- 17 Lee, S. H. – Vigliotti, J. S., et al.: Detection of *Borrelia* in archived sera from patients with clinically suspect Lyme disease. *Int J Mol Sci*, 2014, 15, s. 4284–4298, doi: 10.3390/ijms15034284.
- 18 Janovská, D.: Serologie In: Bartůněk, P.: *Lymeská borelióza*. Praha, Grada, 1996.
- 19 Hulinská, D.: Laboratorní diagnostika. In: Bartůněk, P.: *Lymeská borelióza*. Praha, Grada, 1996.
- 20 Pícha, D.: Lymeská borelióza. *Postgrad Med*, 2009, 11, s. 827–832.
- 21 Nocton, J. J. – Dressler, F. – Rutledge, B. J., et al.: Detection of *Borrelia burgdorferi* DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. *N Engl J Med*, 1994, 330, s. 229–234.
- 22 Wilske, B. – Fingerle, V., et al.: Microbiological and serological diagnosis of Lyme borreliosis. *FEMS Immunol Med Microbiol*, 2007, 49, s. 13–21.
- 23 Steere, A. C. – Levin, R. E. – Molloy, P. J., et al.: Treatment of Lyme arthritis. *Arthritis Rheum*, 1994, 6, s. 878–888.
- 24 Girschick, H. J. – Morbach, H. – Tappe, D.: Treatment of Lyme borreliosis. *Arthritis Res Ther*, 2009, 11, s. 258.
- 25 Dlouhý, P. – Honegr, K., et al.: Doporučený postup v diagnostice, léčbě a prevenci. Lymeská borelióza: Doporučený postup v diagnostice, léčbě a prevenci. Doporučený postup Společnosti infekčního lékařství České lékařské společnosti J. E. Purkyně. Schváleno na zasedání přednostů a primářů infekčních klinik a oddělení ČR, 13.–15. 4. 2011, <http://www.infekce.cz/DoporLB11.htm>.
- 26 Coumou, J. – van der Poll, T., et al.: Tired of Lyme borreliosis. *The Netherlands Journal of Medicine*, 2011, 69, s. 3.
- 27 Wormser, G. P. – Nadelman, R. B., et al.: Practical guidelines for the treatment of Lyme disease. *Clin Infect Dis*, 2000, 31, s. S1–S14.
- 28 Weinstein, A. – Britchkov, M.: Lyme arthritis and post-Lyme disease syndrome. *Cur Opin Rheumatol*, 2002, 14, s. 383–387.
- 29 Priem, S. – Klimberg, T. – Franz, J., et al.: Comparison of reculture and PCR for detection of *Borrelia burgdorferi* in cell and tissue cultures after antibiotic treatment. *Arthritis Rheum*, 2001, 44, s. S1766.
- 30 Malawista, S. E. – Barhold, S. W. – Persing, D. H.: Fate of *Borrelia burgdorferi* DNA in tissue coinfecting mice after antibiotic treatment. *J Infect Dis*, 1994, 170, s. 1312–1316.
- 31 Hodzic, E. – Imai, D., et al.: Resurgence of persisting non-cultivable *Borrelia burgdorferi* following antibiotic treatment in mice. *PLoS ONE*, doi: 10.1371/journal.pone.0086907.
- 32 Carlson, D. – Hernandez, J. – Bloom, B. J., et al.: Lack of *Borrelia burgdorferi* DNA in synovial samples from the patients with antibiotic treatment—resistant Lyme arthritis. *Arthritis Rheum*, 1999, 42, s. 2705–2709.
- 33 Stanek, G. – Kahl, O.: Chemoprophylaxis for Lyme borreliosis? *Int J Med Microbiol Virol Parasitol Infect Dis*, 1999, 289, s. 655–665.
- 34 Shapiro, E. D. – Gerber, M. A. – Holabird, N. B., et al.: A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites. *N Engl J Med*, 1992, 327, s. 1769–1773.
- 35 Nadelman, R. B. – Nowakowski, J. – Fish, D., et al., for the tick bite study group: Prophylaxis with single-dose doxycycline for prevention of Lyme disease after an Ixodes scapularis tick bite. *N Engl J Med*, 2001, 345, s. 79–84.
- 36 Steere, A. C. – Sikand, V. – Meurice, F., et al.: Vaccination against Lyme disease with recombinant *Borrelia burgdorferi* outer-surface lipoprotein A with adjuvant. *N Engl J Med*, 1998, 339, s. 209–215.
- 37 Sigal, L. H. – Zahradnik, J. M. – Lavin, P., et al.: A vaccine consisting of recombinant *Borrelia burgdorferi* outer-surface protein A to prevent Lyme disease. *N Engl J Med*, 1998, 339, s. 216–222.
- 38 Dai, J. – Wang, P., et al.: Antibodies against a tick protein, Salp15, protect mice from the Lyme disease agent. *Cell Host Microbe*, 2009, 6, s. 482–492.
- 39 Rose, C. D. – Fawcett, P. T. – Gibney, K. M.: Arthritis following recombinant outer surface protein A vaccination for Lyme disease. *J Rheumatol*, 2001, 184, s. 174–180.
- 40 Cerar, D. – Cerar, T. – Ruzic-Sabljic, E., et al.: Subjective symptoms after treatment of early Lyme disease. *Am J Med*, 2010, 123, s. 79–86.